Evidence map›Paper›PMID 37278302›Full record

ArticleJournal of viral hepatitis2023

Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia.

Mauricio Lisker-Melman, Wendy C King, Marc G Ghany, Raymond T Chung, Amanda S Hinerman, Gavin A Cloherty, Mandana Khalili, Mamta K Jain, Mark Sulkowski, Richard K Sterling

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Mauricio Lisker-MelmanDivision of Gastroenterology, Washington University School of Medicine and John Cochran VA Medical Center, St. Louis, Missouri, USA.
Wendy C KingSchool of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marc G GhanyLiver Diseases Branch, NIDDK, NIH, Bethesda, Maryland, USA.
Raymond T ChungLiver Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Amanda S HinermanEpidemiology Department, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Gavin A ClohertyAbbott Diagnostics, Lake Forest, Illinois, USA.
Mandana KhaliliDivision of Gastroenterology, Department of Medicine, University of California at San Francisco, San Francisco, California, USA.
Mamta K JainDivision of Gastroenterology, Department of Medicine, UT Southwestern Medical Center & Parkland Health & Hospital System, Dallas, Texas, USA.
Mark SulkowskiDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Richard K SterlingDivision of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA.
University of Pittsburgh · USAbbott (United States) · USJohn Cochran VA Medical Center · USJohns Hopkins University · USMassachusetts General Hospital · USNational Institutes of Health · USParkland Health & Hospital System · USUniversity of California, San Francisco · USVirginia Commonwealth University · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI REBECCA G WELLS · 1997 to 2026
$32.5M
Hepatitis B Research Network - Data Coordination CenterU01DK082864 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELLE, STEVEN H. · 2008 to 2019
$25.3M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
Hepatitis B Research Network (HBRN): Natural History and Treatment StudiesU01DK082944 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COOPER, STEWART, KHALILI, MANDANA · 2008 to 2019
$10.0M
Observation Study of Persons with Chronic Hepatitis B Virus infection in North AmericaU01DK082874 · NIDDK · UNIVERSITY HEALTH NETWORK · PI JANSSEN, HARRY · 2008 to 2019
$6.9M
Harvard Hepatitis B ConsortiumU01DK082919 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHUNG, RAYMOND T, LAU, DARYL T · 2008 to 2019
$4.7M
Midwest Hepatitis B ConsortiumU01DK082871 · NIDDK · SAINT LOUIS UNIVERSITY · PI DI BISCEGLIE, ADRIAN MICHAEL · 2008 to 2019
$4.7M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1 TR001111NCATS NIH HHS UM1 TR004406NCRR NIH HHS M01 RR000040NCRR NIH HHS UL1 RR024986NIAAA NIH HHS K24 AA022523NIDA NIH HHS K24 DA034621NIDDK NIH HHS P30 DK050306NIDDK NIH HHS R01 DK094818NIDDK NIH HHS U01 DK082843NIDDK NIH HHS U01 DK082863NIDDK NIH HHS U01 DK082864NIDDK NIH HHS U01 DK082866NIDDK NIH HHS U01 DK082867NIDDK NIH HHS U01 DK082871NIDDK NIH HHS U01 DK082872NIDDK NIH HHS U01 DK082874NIDDK NIH HHS U01 DK082919NIDDK NIH HHS U01 DK082923NIDDK NIH HHS U01 DK082927NIDDK NIH HHS U01 DK082943NIDDK NIH HHS U01 DK082944
6 · The paper itself

Abstract

Hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg), reflecting transcriptional activity of covalently closed circular DNA, are gaining traction as important markers to assess viral activity. Whether their expression differs under viral suppression by HIV co-infection status is unknown. Among adults with chronic HBV on antiviral therapy, we sought to determine if the expression of HBV markers (specialized and well-established) differs between HBV-HIV co-infection vs. HBV mono-infection. We compared HBV marker levels among 105 participants in the Hepatitis B Research Network (HBRN) HBV-HIV Ancillary Study and 105 participants in the HBRN mono-infected Cohort Study, matched for HBeAg status and HBV DNA suppression on therapy. Among HBeAg+ participants (N = 58 per group), after adjusting for age, sex, race, ALT and HBV DNA, viral markers were higher (p < .05) in the HBV-HIV versus the HBV-only sample (HBeAg: 1.05 vs. 0.51 log

Indexed as

CoinfectionHepatitis BHepatitis B, ChronicHIV InfectionsAdultAntiviral AgentsBiomarkersCohort StudiesDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHIVHumansRNAAntiviral AgentsBiomarkersDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensRNAHBcrAgHBVHBV RNAHIVserum biomarkers

Identifiers

PMID37278302
PMCPMC10524380
OpenAlexW4379509012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.